Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 K57N |
Therapy | Panitumumab |
Indication/Tumor Type | colorectal cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 K57N | colorectal cancer | resistant | Panitumumab | Preclinical | Actionable | In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315). | 26644315 |
MAP2K1 K57N | colorectal cancer | resistant | Panitumumab | Case Reports/Case Series | Actionable | In a retrospective analysis, two patients with metastatic RAS/BRAF wild-type colorectal cancer demonstrated progressive disease following treatment with Vectibix (panitumumab) and via analysis of archived pretreatment tumor biopsy samples and post-progression liquid biopsy both were found to harbor MAP2K1 K57N (PMID: 36419886). | 36419886 |
PubMed Id | Reference Title | Details |
---|---|---|
(26644315) | Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. | Full reference... |
(36419886) | Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. | Full reference... |